COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi completes acquisition of Vicebio
04/12/2025
Sanofi completes acquisition of Vicebio Paris, December 4, 2025 . Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”) . This acquisition brings an early-stage combination vaccine candidate for [...]
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
04/12/2025
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the [...]
Merakris Therapeutics Announces Completion of Type C Meeting with FDA – Alignment on MTX-001 Biologic Drug Development Pathway
04/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative biologic drug therapies for chronic wounds, announced [...]
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
04/12/2025
Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global [...]
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
04/12/2025
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the [...]
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
04/12/2025
PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio , a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea , a leading global contract research [...]
Microbix Announces Initiation of Normal Course Issuer Bid
04/12/2025
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ) (“Microbix” or the “Company”), a [...]
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
04/12/2025
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding [...]
Atavistik Bio to Present Discovery of JAK2 V617F Mutant-Selective Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms (MPNs) at ASH 2025
04/12/2025
Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 Atavistik Bio’s [...]
2025 Cannabis Holiday Gift Guide Highlights Canada’s Most Popular Cannabis Products for the Holiday Season
04/12/2025
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired [...]
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
04/12/2025
ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported [...]
RadioMedix and Thor Medical enter supply agreement for thorium-228
04/12/2025
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical- [...]
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
04/12/2025
Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“ Vaxil ” or the “ Company ”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its [...]
Changes to Tecan’s Board of Directors proposed to shareholders at the upcoming Annual General Meeting 2026
04/12/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, December 4, 2025 – Tecan Group Ltd. (SIX Swiss Exchange: TECN) today announced that the Board of Directors [...]
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
04/12/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
04/12/2025
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment [...]
Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity
04/12/2025
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling [...]
Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
04/12/2025
San Diego, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003 , the company’s intravenous (IV) Deciparticle ™ [...]

Pages